secwatch / observer
8-K filed February 3, 2026, 6:59 PM ET ticker AMRX CIK 0001723128
debt confidence high sentiment positive materiality 0.55

Amneal reprices $2.1B term loan, margin cut 50 bps, saving ~$11M/year

Amneal Pharmaceuticals, Inc.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.95

Amneal Pharmaceuticals, Inc. amended credit facility of $1,960,076,527.50 with JPMorgan Chase Bank, N.A. at 2.00% (for base rate) and 3.00% (for SOFR) maturing August 1, 2032.

Instrument
credit facility
Principal
$1,960,076,527.50
Counterparty
JPMorgan Chase Bank, N.A.
Rate
2.00% (for base rate) and 3.00% (for SOFR)
Maturity
August 1, 2032
Event
amendment
Exact text from the filing
on a cashless basis, its term loans outstanding immediately prior to the Repricing Amendment (the “Existing Term Loans) into new term loans with an aggregate principal amount of $1,960,076,527.50 (collectively, the “Converted Amendment No. 2 Term Loans”) and (y) the Company incurred a new term loan with an aggregate principal amount of $134,673,472.50 (the “Additional
View on SEC.gov
Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.95

Amneal Pharmaceuticals, Inc. incurred term loan of $134,673,472.50 with JPMorgan Chase Bank, N.A. maturing August 1, 2032.

Instrument
term loan
Principal
$134,673,472.50
Counterparty
JPMorgan Chase Bank, N.A.
Maturity
August 1, 2032
Event
incurrence
Exact text from the filing
the Company incurred a new term loan with an aggregate principal amount of $134,673,472.50 (the "Additional Amendment No. 2 Term Loan")
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Amneal Pharmaceuticals, Inc. amended Amendment No. 2 to Term Loan Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the other lenders party thereto (effective 2026-02-02).

Action
amendment
Agreement
credit facility
Counterparty
JPMorgan Chase Bank, N.A., as administrative agent, and the other lenders party thereto
Effective
2026-02-02
Exact text from the filing
On February 2, 2026, Amneal Pharmaceuticals, Inc.’s (the "Corporation") subsidiary, Amneal Pharmaceuticals LLC (the “Company” or, the “Borrower”), and certain of the Company’s subsidiaries, as guarantors, entered into that certain Amendment No. 2 to Term Loan Credit Agreement (the “Repricing Amendment”) with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), and the other lenders party thereto consenting to the Repricing Amendment.
View on SEC.gov

306 debt financings filed in the last 30 days. Browse all debt financings →

Amneal Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR
accession 0001628280-26-004738
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.